AB0758 Change in Weight from Baseline during the Palace Clinical Trial Program with Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
2014 ◽
Vol 73
(Suppl 2)
◽
pp. 1055.1-1055
◽
2015 ◽
Vol 74
(Suppl 2)
◽
pp. 355.3-356
◽
2014 ◽
Vol 73
(Suppl 2)
◽
pp. 90.2-91
◽
2014 ◽
Vol 73
(Suppl 2)
◽
pp. 1050.2-1050
◽
2014 ◽
Vol 73
(Suppl 2)
◽
pp. 742.2-743
◽
2015 ◽
Vol 74
(Suppl 2)
◽
pp. 133-134
◽
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 608.1-608
2017 ◽
Vol 76
(6)
◽
pp. AB47
2016 ◽
Vol 31
(3)
◽
pp. 498-506
◽